HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gottlieb, S. S. Articles by Liittschwager, E. B. Search for Related Content PubMed PubMed Citation Articles by Gottlieb, S. S. Articles by Liittschwager, E. B.

Effects of BG9719 (CVT-124), an A₁-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

Stephen S. Gottlieb, MD, FACC^*, Sandra L. Skettino, MD, Andrew Wolff, MD, Evan Beckman, MD, Michael L. Fisher, MD, FACC^*, Ronald Freudenberger, MD, FACC^*, Tim Gladwell, PharmD^*, Joanne Marshall, RN^*, Michelle Cines, RN^*, Donald Bennett, PhD and Elizabeth B. Liittschwager, BA

^* Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA and the D.V.A. Medical Center, Baltimore, Maryland
CV Therapeutics, Palo Alto, California, USA
Biogen, Cambridge, Massachusetts, USA

View larger version (25K): [in a new window]   Figure 1 The GFR for 11 patients following administration of placebo, furosemide and BG9719. The mean GFR was 63 ± 18 ml/min/1.73m2 following furosemide, 84 ± 23 after receiving placebo and 82 ± 24 ml/min/1.73m2 following BG9719 administration. The difference between furosemide and both placebo and BG9719 was significant, p < 0.005. GFR = glomerular filtration rate.

View larger version (24K): [in a new window]   Figure 2 The renal plasma flow for each patient following administration of placebo, furosemide and BG9719. There were no significant differences among the groups.

View larger version (25K): [in a new window]   Figure 3 The sodium excretion for each patient for the 2 h following administration of placebo, furosemide and BG9719. Sodium excretion increased with both BG9719 (p < 0.005) and furosemide (p < 0.05).